Patient Privacy

World Privacy Forum testifies at FDA advisory committee hearing on the iPledge program; requests attention to privacy issues

iPledge Program | FDA — The World Privacy Forum testified before the Dermatologic and Ophthalmic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the Food and Drug Administration regarding privacy issues related to iPledge, a mandatory program for patients taking the drug Accutane or isotretinoin generics. The FDA has stated that the program, which it requires four drug manufacturers to have in place, does not fall under HIPAA. The program collects substantive amounts of patient information. The Forum urged the FDA to set privacy standards for all RiskMAPs in general, and to resolve privacy issues in the iPledge program specifically. The Forum requested that all marketing provisions of the iPledge program privacy policy be removed, that patients be expressly informed the program does not fall under HIPAA, and that patients be given a printed copy of the iPledge program privacy policy, among other requests.

World Privacy Forum Requests That CMS Bring Its Medicare Part D Data Activities Under HIPAA and Require Certificates of Confidentiality to Protect Patient Privacy

Medical privacy | Medicare Part D — In comments filed with the Centers for Medicare and Medicaid Services, the World Privacy Forum requested that CMS give effect to data restrictions that Congress has expressly included in the law. WPF also requested that CMS include in its standard agreements for use of CMS data a requirement that the recipient obtain a certification of confidentiality for all identifiable CMS data. WPF also requested that CMS perform a regulatory impact analysis and publish a system of records notice.

World Privacy Forum Comments on Proposed Policy for Genetic Database

Genetic privacy — Genome-wide association studies present complex and challenging privacy issues. The National Institutes of Health, in a published request for information, asked for public comment on its proposed policy regarding its support and management of a central genomic repository for genome-wide association studies. In comments filed with the National Institutes of Health, the World Privacy Forum raised concerns about the proposed NIH policy in the specific areas of genetic identifiability, secondary uses of the genetic data, oversight, legal protections, and informed consent.

World Privacy Forum Comments on Privacy Issues Relating to a Nationwide Genetic Research Project

Genetic privacy — The collection of DNA material from 500,000 to 1,000,000 or more individuals as part of a large U.S. medical research project raises many challenging ethical, legal, and privacy issues. An advisory committee reporting to the Office of the Secretary of Health and Human Services ( the Secretary’s Advisory Committee on Genetics, Health and Society) has published a detailed analysis of the issues such a project and its associated databases and biobanks would raise in a draft report. The committee’s final report and policy recommendations will be submitted to the Secretary of HHS. The World Privacy Forum has submitted public comments on the draft; the comments include key policy recommendations.
The Forum’s recommendations include the need to provide protection from compelled disclosure of information, the necessity for a full-time project privacy officer with enforcement power, the need to address identifiability issues, and the need for a far-reaching and robust privacy policy that exceeds the requirements of HIPAA, among other recommendations.

World Privacy Forum Comments to HHS on Protecting Patient Choice and Expanding Medical Privacy Rights

Medical privacy — The World Privacy Forum filed comments with Health and Human Services this week asking the agency to protect patient choice and privacy. The World Privacy Forum asked that patients continue to be able to receive accounting of disclosures under HIPAA, and asked that this important patient right under HIPAA not be removed or weakened. The World Privacy Forum also asked HHS to review how patients’ records can be amended under HIPAA, and recommended that in light of the coming National Health Information Network, that changes to enhance patient choice may be needed in this area.